Clinical trials: Adverse Drug Related Events
Drug-Related Side Effects and Adverse Reactions
Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
It concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine.
- Trial name
- NCT03938597
- Where
- Brazil
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Adverse Drug Events
Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes
Adverse drug events (ADEs) are the most clinically significant and costly medication-related problems in nursing homes (NH) and are associated with an estimated 93,000 deaths a year and as much as $4 billion of excess healthcare…
- Trial name
- NCT01531088
- Testing
- Active medication monitoring
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Self Efficacy, Adverse Drug Event
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
assess the activity and toxicity of second-line treatment with pazopanib after failure of first-line sunitinib treatment in patients with clear cell mRCC; to investigate the potential association of DLL4, Notch1, VEGFA, PDGFRB…
- Conditions
- Self Efficacy, Adverse Drug Event, Carcinoma, Renal Cell
- Trial name
- NCT02324803
- Testing
- pazopanib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Southern China Urology Cancer Consortium
HIV Infections, Neutropenia
Study to Improve Survival Among HIV-Exposed Infants in Botswana
The purpose of this study is to find ways to improve infant health and survival among infants whose mothers are HIV-infected but who do not themselves have HIV.
- Conditions
- HIV Infections, Neutropenia, Anemia
- Trial name
- Mpepu (NCT01229761)
- Testing
- cotrimoxazole prophylaxis, exclusive breastfeeding until 6 months of age, breastfeeding for 12 months
- Where
- 3 sites in Botswana
- Volunteers
- 3,724 people
- Sponsor
- Harvard School of Public Health (HSPH)
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04339634
- Testing
- Simulation of Repurposed Drugs for COVID-19
- Where
- United States
- Volunteers
- 12,873 people
- Sponsor
- Tabula Rasa HealthCare
Colorectal Adenocarcinoma, Oesogastric
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related…
- Trial name
- NCT04894123
- Testing
- Trifluridine/Tipiracil, Oxaliplatin
- Where
- 11 sites in France
- Volunteers
- 1 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Cancer, Cardiac Toxicity
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for…
- Conditions
- Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
- Trial name
- PACE in BC (NCT00875238)
- Testing
- trastuzumab, doxorubicin hydrochloride, polymorphism analysis
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vanderbilt University
Tuberculosis, Drug-Induced Liver Injury
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
A clinical trial to investigate the appropriate dose of isoniazid according to NAT2 polymorphism status in Korean subjects
- Conditions
- Tuberculosis, Drug-Induced Liver Injury, Adverse Drug Event
- Trial name
- NCT03665402
- Testing
- Isoniazid
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Adverse Drug Event
Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention
Reducing medications and associated side effects in older adults: an electronic hospital-based intervention
- Trial name
- NCT03272607
- Testing
- Deprescribing opportunities
- Where
- 7 sites in Canada
- Volunteers
- 6,582 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Human Immunodeficiency Virus
Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration
Hypothesis: Patients using enfuvirtide with the Biojector have an improved quality of life, greater satisfaction, and fewer adverse events compared with using the standard needle.
- Trial name
- NCT00333736
- Testing
- Biojector
- Where
- Canada
- Volunteers
- 337 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV Infection, Adverse Drug Reaction
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable HIV-infected adult patients receiving combination therapy will demonstrate improved clinical tolerability or lipid profiles with sustained…
- Conditions
- HIV Infection, Adverse Drug Reaction, Quality of Life
- Trial name
- TaISENWITCH (NCT01679964)
- Testing
- Raltegravir switch
- Where
- 7 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- Lin, Hsi-Hsun, M.D.
Adverse Drug Event, Non-Adherence, Medication
Evaluating ActionADE on Adverse Drug Event Due to Non-Adherence
Repeat non-adherence to medications is a common cause of preventable adverse drug events. Health information technologies have the potential to improve information continuity.
- Trial name
- NCT04574648
- Testing
- ActionADE
- Volunteers
- 2,000 people
- Sponsor
- University of British Columbia
Adverse Drug Events, Adverse Drug Reactions
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
To highlight the incidence of adverse reactions of Qingkailing Injection.
- Trial name
- NCT01764204
- Testing
- Qingkailing Injection
- Where
- 48 sites in China
- Volunteers
- 30,840 people
- Sponsor
- China Academy of Chinese Medical Sciences
Pain, Quality of Life
FLUAD® vs. Fluzone® High-Dose Study
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug
- Trial name
- NCT03183908
- Testing
- FLUAD®, Fluzone® High-Dose
- Where
- 4 sites in United States
- Volunteers
- 757 people, healthy volunteers welcome
- Sponsor
- Duke University
Adverse Drug Event
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
Emergency departments (EDs) are a crucial element of health care systems as they constitute the interface between hospital and communities.
- Trial name
- URGEIM (NCT03725046)
- Testing
- Optimized information transmission
- Where
- France
- Volunteers
- 346 people
- Sponsor
- University Hospital, Montpellier
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Adverse Drug Event, Adverse Drug Reaction
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
This registry aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.
- Conditions
- Adverse Drug Event, Adverse Drug Reaction, Chinese Medicine, Anaphylactic Reaction
- Trial name
- NCT02559960
- Testing
- Breviscapine Powder-Injection
- Where
- 15 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Zhong Wang
Adverse Drug Events (ADEs)
Enhancing the Safety of Warfarin in Nursing Homes
Oral anticoagulant therapy with warfarin is essential for the prevention of strokes and other thromboembolic events related to various medical conditions; however, use of this therapy can be associated with an increased risk of…
- Trial name
- NCT00682773
- Testing
- SBAR
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Opioid-induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced…
- Trial name
- NCT03720613
- Testing
- Naldemedine, Lubiprostone, Naloxegol
- Where
- United States
- Volunteers
- 34,532 people
- Sponsor
- BioDelivery Sciences International
Kidney Failure, Acute
Achieving Medication Safety During Acute Kidney Injury
The utilization of clinical decision support (CDS) is increasing among healthcare facilities which have implemented computerized physician order entry or electronic medical records.
- Trial name
- NCT01134900
- Testing
- Pharmacy Dashboard Review and Intervention
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Vanderbilt University